Aziz, D.; Mohamed, S.A.; Tayel, S.; Makhlouf, A.
Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study. Pharmaceutics 2022, 14, 1746.
https://doi.org/10.3390/pharmaceutics14081746
AMA Style
Aziz D, Mohamed SA, Tayel S, Makhlouf A.
Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study. Pharmaceutics. 2022; 14(8):1746.
https://doi.org/10.3390/pharmaceutics14081746
Chicago/Turabian Style
Aziz, Diana, Sally A. Mohamed, Saadia Tayel, and Amal Makhlouf.
2022. "Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study" Pharmaceutics 14, no. 8: 1746.
https://doi.org/10.3390/pharmaceutics14081746
APA Style
Aziz, D., Mohamed, S. A., Tayel, S., & Makhlouf, A.
(2022). Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study. Pharmaceutics, 14(8), 1746.
https://doi.org/10.3390/pharmaceutics14081746